
	Year Ended March 31, 2026
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2025	$	2,136,986	$	434,500	$	2,571,486
Additions (a)	—		13,865		13,865



Effects of foreign currency exchange rates	6,689		1,765		8,454
Balance – March 31, 2026	$	2,143,675	$	450,130	$	2,593,805

Accumulated Amortization
Balance – March 31, 2025	$	—	$	276,136	$	276,136
Additions	—		17,919		17,919

Effects of foreign currency exchange rates	—		145		145
Balance – March 31, 2026	$	—	$	294,200	$	294,200

Intangible assets, net – March 31, 2026	$	2,143,675	$	155,930	$	2,299,605

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,068,752	$	138,903	$	2,207,655
International OTC Healthcare	74,923		17,027		91,950

Intangible assets, net – March 31, 2026	$	2,143,675	$	155,930	$	2,299,605


	Year Ended March 31, 2025
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2024	$	2,167,162	$	411,258	$	2,578,420
Additions (a)	6,850		1,400		8,250
Reclassifications (b)	(28,982)		28,982		—

Tradename impairment	(6,552)		(5,914)		(12,466)
Effects of foreign currency exchange rates	(1,492)		(1,226)		(2,718)
Balance – March 31, 2025	$	2,136,986	$	434,500	$	2,571,486

Accumulated Amortization
Balance – March 31, 2024	$	—	$	257,837	$	257,837
Additions	—		18,263		18,263

Effects of foreign currency exchange rates	—		36		36
Balance – March 31, 2025	$	—	$	276,136	$	276,136

Intangible assets, net – March 31, 2025	$	2,136,986	$	158,364	$	2,295,350

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,068,752	$	141,234	$	2,209,986
International OTC Healthcare	68,234		17,130		85,364

Intangible assets, net – March 31, 2025	$	2,136,986	$	158,364	$	2,295,350

(a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us the rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.

During the fourth quarter of each fiscal year, in conjunction with our strategic planning process, we perform our annual impairment analysis for intangible assets. We utilized the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The assumptions subject to significant uncertainties in the analysis include the discount rate, as well as future sales, gross margins and advertising and marketing expenses. The discount rate assumption may be influenced by such factors as changes in interest rates and rates of inflation, which can have an impact on the determination of fair value. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer needs or preferences, technological advances, changes in advertising and marketing expenses, or the potential impacts of supply chain constraints, labor shortages, or inflation, we may be required to record additional impairment charges in the future.

At February 29, 2024, in conjunction with the annual test for impairment of intangible assets, the estimated fair value exceeded the carrying value for all intangible assets and accordingly, no impairment charge was taken.

As part of our annual impairment test conducted on February 28, 2025, we recognized impairment charges for indefinite-lived intangible assets totaling $6.6 million. These charges pertain to non-strategic indefinite-lived intangible assets, reflecting a deliberate shift in sales toward other strategic brands within our portfolio. Of the $6.6 million impairment, $4.1 million was associated with our North American OTC Healthcare segment, while $2.4 million impacted our International OTC Healthcare segment.

At February 28, 2026, in conjunction with the annual test for impairment of intangible assets, the estimated fair value exceeded the carrying value for all intangible assets and accordingly, no impairment charge was taken.

Our analysis as of February 28, 2026 confirmed that all indefinite-lived intangible assets had a fair value exceeding their carrying value by at least 10%, with the exception of Monistat within our North American Women's Health reporting unit. We performed a sensitivity analysis of our weighted average cost of capital, and we determined that a 50-basis point increase in the

weighted average cost of capital used to value all of our indefinite-lived intangible assets would have resulted in an impairment charge of $16.6 million. Additionally, a 50-basis point decrease in the terminal growth rate used for each of our indefinite-lived intangible assets would have not have resulted in any of our indefinite-lived intangible assets' fair value being less than their carrying value.

The weighted average remaining life for finite-lived intangible assets at March 31, 2026 was approximately 9.0 years, and the amortization expense for the year ended March 31, 2026 was $17.9 million. At March 31, 2026, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which range from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):